Researchers at Johns Hopkins and their collaborators conducted an open-label phase I clinical trial of a new treatment, in which a viral vector expressing the gene for sFLT01, a protein that ...

Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research ...

The five-year trial saw patients who received a single injection of Lumevoq sustaining clinical recovery in a rare condition ...

Unlike older male eye cells, which showed a consistent immune response pattern, older female eye cells appeared to experience ...

D Molecular Therapeutics Inc.’s gene therapy, 4D-150, in wet age-related macular degeneration (wet AMD) produced positive phase IIb data as the company preps two phase III studies set to begin this ...

Goldman Sachs downgraded Regenxbio Inc (NASDAQ:RGNX), citing gene therapy’s appeal for wet AMD and diabetic retinopathy is ...

Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found. The ...

Last year, it claimed a $370 million licensing deal with AbbVie for an AAV8 gene therapy candidate RGX-314 for wet age-related macular degeneration (AMD).

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Ocugen (OCGN) announced that dosing is complete, ahead of schedule in the Phase 2 portion of the Phase 1/2 ArMaDa clinical trial for OCU410-a ...

Goldman Sachs downgraded Regenxbio (RGNX) to Neutral from Buy with a price target of $14, down from $38. The firm has questions over the ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of pipeline dry AMD therapies in various stages of clinical development, major ...